UBS and Reed confirm £900m life sciences deal with GSK

Post the COVID-19 pandemic, the importance of a high-class life science industry is self-evident. Yet the scale of the industry, and the resources required to sustain it, are perhaps still underappreciated. In our white paper, we looked at repositioning secondary office sites into life sciences assets.

UBS is doing just that with this exciting development in the Golden Triangle.

To view the article, please click here.